#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Pharmacist-led academic detailing improves statin therapy prescribing for Malaysian patients with type 2 diabetes: Quasi-experimental design


Autoři: Mohamed Hassan Elnaem aff001;  Mohamad Haniki Nik Mohamed aff001;  Hasniza Zaman Huri aff002
Působiště autorů: Department of Pharmacy Practice, Faculty of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang, Malaysia aff001;  Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia aff002
Vyšlo v časopise: PLoS ONE 14(9)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0220458

Souhrn

Objective

Previous reports have highlighted the suboptimal utilization and prescription of statin therapy among patients with type 2 diabetes mellitus (T2DM) in the Malaysian clinical practice. This study aims to test the impact of a pharmacist-led academic detailing program on improving the overall statin therapy prescribing in Malaysian hospital and primary care settings.

Methods

As a quasi-experimental design with a control group and pre-tests., we examined 1,598 medical records of T2DM subjects in six healthcare facilities in the state of Pahang, Malaysia. In all study sites, there was a pre and post-intervention assessment of the percentage of appropriate statin therapy prescribing that complied with the clinical guidelines with no potential safety issues. The intervention was an academic detailing program offered to the health care providers in three study sites, while the other three sites served as the control group. A comparison of the overall percentage of appropriate statin therapy prescribing before and after the academic detailing was performed in all intervention and control sites.

Results

Overall, 797 medical records were examined in the pre-intervention phase, and 801 records were evaluated in the post-intervention phase. The academic detailing program was associated with a statistically significant difference in the proportion of appropriate statin therapy prescribing between the post-intervention phase compared to the pre-intervention phase (n = 246, 61.7% versus n = 188, 47.1%), p = 0.001. Whereas, the appropriate statin therapy prescribing in the control study sites experienced a modest change from 53.8% (214/398) to 56.7% (228/402), p = 0.220. The academic detailing showed significant increases in the proportions of appropriate statin therapy prescribing in both hospital and primary care settings.

Conclusions

The academic detailing program was found to be significantly associated with a positive impact on the overall statin therapy prescribing among patients with T2DM in Malaysian hospital and primary care settings.

Klíčová slova:

Medicine and health sciences – Pharmacology – Drugs – Statins – Health care – Health care providers – Allied health care professionals – Primary care – Endocrinology – Endocrine disorders – Metabolic disorders – Pharmaceutics – Drug therapy – People and places – Population groupings – Professions – Medical personnel – Pharmacists – Biology and life sciences – Biochemistry – Lipids


Zdroje

1. James P, Tan HH, MacAlpine R, Brennan G, Emslie-Smith A, Morris AD. Treatment gap in the use of lipid-lowering drug therapy in diabetes: A population-based study. Diabet Med. 2004;21: 1108–1112. doi: 10.1111/j.1464-5491.2004.01301.x 15384958

2. Elnaem MH, Nik Mohamed MH, Huri HZ, Azarisman SM. Patterns of statin therapy prescribing among hospitalized patients with Type 2 diabetes mellitus in two Malaysian tertiary hospitals. Trop J Pharm Res. 2017;16: 3005–3011. doi: 10.1016/j.jval.2017.08.497

3. Bucheit JD, Helsing H, Nadpara P, Virani SS, Dixon DL. Clinical pharmacist understanding of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. J Clin Lipidol. 2018;12: 367-374.e3. doi: 10.1016/j.jacl.2017.11.010 29277495

4. Wander GS, Jadhav UM, Chemburkar A, Lopez M, Gogtay J. Lipid management in India: a nationwide, cross-sectional physician survey. Lipids in Health and Disease. 2017;16: 130. doi: 10.1186/s12944-017-0519-1 28673294

5. Falk E. Appropriate use of cholesterol-lowering therapy. Atherosclerosis. 2017;262: 198–199. doi: 10.1016/j.atherosclerosis.2017.02.006 28236436

6. Kuiper JG, Sanchez RJ, Houben E, Heintjes EM, Penning-van Beest FJA, Khan I, et al. Use of Lipid-Modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands. Clin Ther. 2017;39: 819-827.e1. doi: 10.1016/j.clinthera.2017.03.001 28347514

7. Lama S, Souraya D, Youssef F. Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients. Int J Clin Pharm. 2017; doi: 10.1007/s11096-017-0483-x 28523462

8. Elnaem MH, Nik Mohamed MH, Zaman Huri H, Azarisman SM. Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings. Ther Clin Risk Manag. 2019;18: 137–145.

9. Doellner JF, Dettloff RW, DeVuyst-Miller S, Wenstrom KL. Prescriber acceptance rate of pharmacists’ recommendations. J Am Pharm Assoc.2017; 1–6. doi: 10.1016/j.japh.2017.03.002 28408169

10. Benedict A, Spence M, Sie J, Chin H, Ngo C, Salmingo J, et al. Evaluation of a Pharmacist-Managed Diabetes Program in a Primary Care Setting Within an Integrated Health Care System. J Manag Care Spec Pharm. 2018;24. doi: 10.18553/jmcp.2018.24.2.114 29384029

11. Naugler C, Cook C, Morrin L, Wesenberg J, Venner AA, Campbell N, et al. Statin Prescriptions for High-Risk Patients Are Increased by Laboratory-Initiated Framingham Risk Scores: A Quality-Improvement Initiative. Can J Cardiol. 2017;33: 682–684. doi: 10.1016/j.cjca.2017.02.005 28449839

12. Thomas JS, Gillard D, Khor M, Hakendorf P, Thompson CH. A comparison of educational interventions to improve prescribing by junior doctors. Q J Med. 2015;108: 369–377. doi: 10.1093/qjmed/hcu213 25322990

13. Avorn J. Academic detailing: “Marketing” the best evidence to clinicians. J Am Med Assoc. 2017;317: 361–362. doi: 10.1001/jama.2016.16036 28118458

14. Wisniewski CS, Robert S, Ball S. Collaboration between a drug information center and an academic detailing program. Am J Heal Pharm. 2014;71: 128–133. doi: 10.2146/ajhp130225 24375605

15. Fischer MA. Academic Detailing in Diabetes: Using Outreach Education to Improve the Quality of Care. Curr Diab Rep. Current Diabetes Reports; 2016;16. doi: 10.1007/s11892-016-0785-8 27586191

16. Godman B, Bishop I, Campbell SM, Malmström RE, Truter I. Quality and efficiency of statin prescribing across countries with a special focus on South Africa; findings and future implications. Expert Rev Pharmacoecon Outcomes Res. 2015;15: 323–330. doi: 10.1586/14737167.2015.967221 25338546

17. Costa J de O, Almeida-Brasil CC, Godman B, Fischer MA, Dartnell J, Heaney A, et al. Implementation of clinical guidelines in Brazil: Should academic detailing be used? J Pharm Heal Serv Res. 2016;7: 105–115. doi: 10.1111/jphs.12133

18. Lowrie R, Lloyd SM, McConnachie A, Morrison J. A cluster randomised controlled trial of a pharmacist-led collaborative intervention to improve statin prescribing and attainment of cholesterol targets in primary care. PLoS One. 2014;9. doi: 10.1371/journal.pone.0113370 25405478

19. Siti Fauziah A, Kamarudin A, O NNAN, Sivasampu S, Rosliza L, Rosaida MS, et al. Malaysian Statistics On Medicines 2009 & 2010. 2014.

20. Said AH, Chia YC. Awareness, knowledge and practice of dyslipidaemia management among postgraduate primary care trainees in Malaysia: a cross-sectional study. BMJ Open. 2017;7: e013573. doi: 10.1136/bmjopen-2016-013573 28249849

21. Simon SR, Majumdar SR, Prosser LA, Salem-Schatz S, Warner C, Kleinman K, et al. Group versus individual academic detailing to improve the use of antihypertensive medications in primary care: A cluster-randomized controlled trial. Am J Med. 2005;118: 521–528. doi: 10.1016/j.amjmed.2004.12.023 15866255

22. Elnaem MH, Nik Mohamed MH, Zaman Huri H, Azarisman SM. Impact of educational outreach intervention on enhancing health care providers’ knowledge about statin therapy prescribing in Malaysian patients with type 2 diabetes mellitus. J Eval Clin Pract. 2018;24: 521–527. doi: 10.1111/jep.12903 29508492

23. Naughton C, Feely J, Bennett K. A clustered randomized trial of the effects of feedback using academic detailing compared to postal bulletin on prescribing of preventative cardiovascular therapy. Fam Pract. 2007;24: 475–480. doi: 10.1093/fampra/cmm044 17670803

24. OpenEpi—Toolkit Shell for Developing New Applications [Internet]. [cited 15 Jul 2019]. Available: http://www.openepi.com/SampleSize/SSPropor.htm

25. Malaysian Clinical Practice Guideline. Management of Type 2 Diabetes Mellitus. 2015; 1–129.

26. Renner HM, Hollar A, Stolpe SF, Marciniak MW. Pharmacist-to-prescriber intervention to close therapeutic gaps for statin use in patients with diabetes: A randomized controlled trial. J Am Pharm Assoc. 2017;57: S236-S242.e1. doi: 10.1016/j.japh.2017.04.009 28506378

27. Gil-Guillen V, Hermida E, Pita-Fernandez S, Palazon-Bru A, Durazo-Arvizu R, Pallares-Carratala V, et al. A cardiovascular educational intervention for primary care professionals in Spain: positive impact in a quasi-experimental study. Br J Gen Pract. 2015;65: e32–40. doi: 10.3399/bjgp15X683137 25548314

28. Tunney RK, Johnson DC, Wang L, Cox ZL. Impact of Pharmacist Intervention to Increase Compliance With Guideline-Directed Statin Therapy During an Acute Coronary Syndrome Hospitalization. Ann Pharmacother. 2017;51: 394–400. doi: 10.1177/1060028016687322 28058865


Článek vyšel v časopise

PLOS One


2019 Číslo 9
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#